Project: Role of metals and metal containing biomolecules in neurodegenerative diseases such as Alzheimer’s disease

New and improved tests will allow patients to access effective treatment through earlier diagnosis Over 6 million people are affected by neurodegenerative diseases in the EU and this number is set to double over the next 20 years. Early diagnosis of Alzheimer’s disease, the most common form of neurodegeneration, can help patients access effective treatments and sources of support, but studies suggest only half of people with the condition have been diagnosed and these cases are often only identified in the advanced stages. One of the key reasons for this is the lack of accuracy involved in the measurement of biomarkers used to indicate Alzheimer’s disease. This project will use the achievements of EMRP project HLT05 Metallomics to improve this accuracy by establishing new reference measurement procedures for established biomarkers in cerebrospinal fluid, found in the brain and spine, while also introducing procedures for potential new blood-based biomarkers. This will support reliable, comparable measurements in current diagnostic tests and further the development of population-based screening through blood testing, which is urgently required to enable earlier diagnosis of Alzheimer’s disease.

Acronym	15HLT02 ReMiND (Reference Number: 15HLT02)
Duration	01/07/2016 - 01/07/2019
Project Topic	Metrology
Project Results (after finalisation)	See Website
Website	visit project website
Network	EMPIR
Call	EMPIR CALL 2015

Project partner

Number	Name	Role	Country
1	Physikalisch-Technische Bundesanstalt	Coordinator	Germany
2	Bundesanstalt fuer Materialforschung und -pruefung	Partner	Germany
3	LGC Limited	Partner	United Kingdom
4	Turkiye Bilimsel ve Teknolojik Arastirma Kurumu	Partner	Türkiye
5	Charite - Universitaetsmedizin Berlin	Partner	Germany
6	Universiteit Gent	Partner	Belgium
7	The University Court of the University of Aberdeen	Partner	United Kingdom
8	Universitat Wien	Partner	Austria